Alkermes (NASDAQ:ALKS) Issues FY 2026 Earnings Guidance

Alkermes (NASDAQ:ALKS) updated its FY 2026 earnings guidance on Wednesday. The company provided EPS guidance of -0.798–0.680 for the period, compared to the consensus EPS estimate of 1.630. The company issued revenue guidance of $1.7 billion-$1.8 billion, compared to the consensus revenue estimate of $1.7 billion.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. Zacks Research downgraded Alkermes from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 19th. Deutsche Bank Aktiengesellschaft cut their price objective on shares of Alkermes from $55.00 to $45.00 and set a “buy” rating for the company in a report on Thursday, November 13th. Truist Financial lifted their price objective on shares of Alkermes from $50.00 to $55.00 and gave the company a “buy” rating in a research report on Monday, November 17th. Wolfe Research initiated coverage on shares of Alkermes in a research report on Monday. They set an “outperform” rating and a $45.00 target price for the company. Finally, Wells Fargo & Company lifted their price target on shares of Alkermes from $37.00 to $43.00 and gave the company an “overweight” rating in a report on Thursday. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $44.07.

Alkermes Price Performance

Shares of Alkermes stock traded down $0.30 during trading hours on Friday, reaching $30.43. The company’s stock had a trading volume of 468,347 shares, compared to its average volume of 2,021,645. The firm has a 50 day moving average price of $31.50 and a 200-day moving average price of $30.18. The stock has a market cap of $5.02 billion, a P/E ratio of 21.29 and a beta of 0.49. Alkermes has a one year low of $25.17 and a one year high of $36.32.

Alkermes (NASDAQ:ALKS) last issued its quarterly earnings data on Wednesday, February 25th. The company reported $0.29 earnings per share for the quarter, missing the consensus estimate of $0.43 by ($0.14). The company had revenue of $384.55 million for the quarter, compared to the consensus estimate of $380.44 million. Alkermes had a return on equity of 14.91% and a net margin of 16.37%.The company’s revenue was down 10.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.05 earnings per share. Alkermes has set its FY 2026 guidance at -0.798–0.680 EPS. As a group, sell-side analysts forecast that Alkermes will post 1.31 EPS for the current fiscal year.

Insider Buying and Selling at Alkermes

In other Alkermes news, EVP Craig C. Hopkinson sold 9,000 shares of the business’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $33.93, for a total transaction of $305,370.00. Following the transaction, the executive vice president owned 57,740 shares in the company, valued at $1,959,118.20. The trade was a 13.49% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Shane Cooke sold 61,200 shares of the stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $34.57, for a total transaction of $2,115,684.00. Following the completion of the sale, the director directly owned 103,744 shares in the company, valued at approximately $3,586,430.08. This represents a 37.10% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 148,148 shares of company stock worth $5,028,378 in the last 90 days. 4.40% of the stock is currently owned by insiders.

Key Alkermes News

Here are the key news stories impacting Alkermes this week:

• Positive Sentiment: Wells Fargo raised its price target on ALKS from $37 to $43 and assigned an “overweight” rating, signaling analyst conviction in upside despite the recent pullback. Wells Fargo price target raise
• Positive Sentiment: Royal Bank of Canada maintained a bullish stance (outperform) and set a $45 target after a technical adjustment, leaving significant implied upside from current levels. RBC rating/target note
• Neutral Sentiment: Reported short-interest data for February is effectively non-informative in the feeds provided (zeros/NaN), so there’s no clear short-squeeze or covering signal driving today’s move.
• Negative Sentiment: Multiple reports indicate Alkermes missed consensus earnings (reported EPS roughly $0.29 vs. ~ $0.43 expected), and headlines tie the miss to a meaningful intraday sell-off. That earnings shortfall is the primary near-term negative catalyst. ALKS shares down after earnings miss
• Negative Sentiment: Alkermes announced a CEO succession/leadership change concurrently with earnings. Management transitions often raise uncertainty about strategy and execution, which can amplify share-price weakness after a disappointing quarter. CEO succession plan
• Negative Sentiment: Market commentary is questioning whether weaker 2025 results plus the leadership change materially alter the bull case for ALKS, adding to downward pressure from cautious investors. Analysis on weaker results and CEO change

Institutional Trading of Alkermes

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Johnson Financial Group Inc. bought a new position in Alkermes in the third quarter worth approximately $31,000. UMB Bank n.a. lifted its holdings in shares of Alkermes by 57.6% in the 4th quarter. UMB Bank n.a. now owns 1,220 shares of the company’s stock worth $34,000 after buying an additional 446 shares during the period. Northwestern Mutual Wealth Management Co. grew its position in shares of Alkermes by 1,041.4% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 1,324 shares of the company’s stock worth $37,000 after buying an additional 1,208 shares in the last quarter. Osaic Holdings Inc. grew its position in shares of Alkermes by 56.4% during the 2nd quarter. Osaic Holdings Inc. now owns 1,945 shares of the company’s stock worth $56,000 after buying an additional 701 shares in the last quarter. Finally, T. Rowe Price Investment Management Inc. purchased a new position in shares of Alkermes during the fourth quarter valued at $59,000. 95.21% of the stock is owned by hedge funds and other institutional investors.

About Alkermes

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.